EGFR-IN-144

EGFR-IN-144 (Compound 4B) exhibits inhibitory activities against EGFR (IC50=0.639 µg/mL) and tubulin polymerization (IC50=7.339 µg/mL) . EGFR-IN-144 exhibits cytotoxicity in multiple cancer cell with GI50 of nanomolare levels. EGFR-IN-144 downregulates the expressions of mTOR, TNF-α, and IL-6, arrests the cell cycle at G1/S phase, and induces apoptosis[1].

Product Specifications

UNSPSC

12352211

Target

Apoptosis; EGFR; Interleukin Related; Microtubule/Tubulin; TNF Receptor

Related Pathways

Apoptosis; Cell Cycle/DNA Damage; Cytoskeleton; Immunology/Inflammation; JAK/STAT Signaling; Protein Tyrosine Kinase/RTK

Field of Research

Cancer

Smiles

COC1=CC=C(C=C1OC)/C=C/C(C2=C(N(N=N2)C3=C(Cl)C=C(Cl)C=C3)C)=O

Molecular Formula

C20H17Cl2N3O3

Molecular Weight

418.27

References & Citations

[1]Shaheen M A, et al. Development of 1, 2, 3-triazole hybrids as multi-faced anticancer agents co-targeting EGFR/mTOR pathway and tubulin depolymerization[J]. Bioorganic Chemistry, 2025: 108153.